Lepodisiran, a long-duration small interfering RNA targeting lipoprotein(a) synthesis, reduced serum concentrations of lipoprotein(a) compared to placebo in adults with elevated levels. 2. Lepodisiran ...

Maximum walking distance at 52 weeks was significantly improved with semaglutide. 2. There were fewer treatment-related serious adverse events in the semaglutide group compared to placebo. Evidence Ra ...